Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
Read more here.
Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
Read more here.
![[OurCrowd in Business Insider] The 25 coolest tech companies in Israel](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
